Preclinical studies have suggested that combining mTOR inhibitors with PD-1 antibodies has synergistic effects across multiple tumor types, including melanoma, hepatocellular carcinoma, head and neck cancer, and others.3–5 Thus, there is a strong rationale to combine these two treatment modalities to improve and prolong antitumor responses in patients with advanced cancer. This evidence concerns the gene MTOR and cancer.